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Abstract: Background: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II 
studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like car-
bamazepine, phenytoin, and oxcarbazepine - as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine - 
are frequently used in patients with GBM. Since CYP3A4 is the major isozyme involved in the metabolism of imatinib, 
we investigated the influence of EIAEDs on imatinib pharmacokinetics (pk). 
Methods: GBM patients received 600 mg imatinib p.o./o.d. in combination with 1.0 g HU p.o./o.d..together with either 
EIAEDs, non-EIAEDs, or no antiepileptic drug (non-AEDs) comedication. Trough plasma levels of imatinib and its active 
main metabolite N-desmethyl-imatinib (CGP74588) were determined biweekly in these patients, total 543 samples being 
collected from 224 patients (up to 6 times / patient). All three groups were compared to each other and with historical 
pharmacokinetic data obtained from patients with chronic myeloid leukemia (CML). 
Results: Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 
ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 
ng/ml, CV 50%). Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated 
with EIAEDs. Only slight, but although significant differences were observed in the mean trough level of the metabolite 
CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%) , 351 ng/ml (CV 34%) and 356 
ng/ml (CV 52%), respectively. The corresponding mean level for CML patients was 300 ng/ml (CV 50%). 
Conclusion: Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs. 
The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or 
compensated by administering higher imatinib doses. In addition these data demonstrate that there is no significant differ-
ence in the pharmacokinetics of imatinib between patients with glioblastoma and CML. 
Key Words: Imatinib, STI571, CGP74588, EIAED, phenytoin, valproate, carbamazepine, oxcarbazepine, topiramate, lamotri-
gine, levetiracetam, pharmacokinetics, main metabolite, cytochrome P450, CYP3A4, glioblastoma multiforme, CML. 
INTRODUCTION
  Glioblastoma multiforme (GBM) is the most frequent 
primary malignant intracranial tumor in adults. Despite ad-
vances in multidisciplinary treatment approaches like neuro-
surgery, radiation and chemotherapy the overall prognosis 
remains poor with a median survival between 12 and 18 
months after diagnosis. Recurrence under optimal treatment 
including chemotherapy with temozolomide seems to be 
nearly unavoidable. Following progression the available 
therapies like surgical reintervention, external beam radio-
therapy and salvage chemotherapy provide a limited survival 
benefit [1-6]. 
  In search of new treatment strategies preclinical and 
clinical research focussed on novel agents targeting distinct 
signaling pathways. CNS malignancies including GBM were  
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found to express epithelial growth factor-receptor (EGF-R) 
and platelet derived growth factor-receptor (PDGF-R). 
Imatinib mesylate (STI571, Gleevec) is a selective inhibitor 
of the tyrosine kinases BCR-ABL, c-KIT and PDGF-R and 
has been shown to be highly active in chronic myeloid leu-
kemia (CML) and has significant antitumor efficacy against 
gastrointestinal stroma tumors (GIST). In GBM only modest 
responses could be reached if imatinib is used as a single 
agent. In contrast, a combination of 600mg imatinib with 
1000mg Hydroxyurea (HU) daily leads to an increased re-
sponse rate in patients with progressive GBM. Currently, the 
mechanism underlying the enhanced activity of this combi-
nation regime is not well understood [7-14].  
  Concomitant administration of enzyme-inducing antiepi-
leptic drugs (EIAEDs) as well as non enzyme-inducing 
antiepileptic drugs (non-EIAEDs) are a common therapy in 
patients with brain tumors. The EIAEDs carbamazepine and 
phenytoin are potent inducers of cytochrome P450 isoen-
zyme CYP3A4, whereas oxcarbazepine and topiramate are 
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levetiracetam and maybe lamotrigine are most likely not 
involved in drug interactions. Valproic acid slightly inhibits 
CYP3A4 activity and is able to significantly displace drugs 
from plasma albumin. Imatinib is metabolised mainly by 
cytochromeP450 CYP3A4 to its main metabolite CGP74588 
that has similar in vitro activity to the parent compound. 
Therefore significant interactions may occur between 
imatinib and EIAEDs leading to changes in plasma concen-
tration of imatinib, CGP74588 as well as coadministered 
drugs. Some studies have investigated the effects of EIAEDs 
on the pharmacokinetics of imatinib and CGP74588 [15-21, 
25]. They demonstrated that EIAED’s could lead to a sub-
stantially decreased plasma exposure of imatinib. In patients 
receiving imatinib for chronic myelogenous leukemia and 
gastrointestinal stromal tumors they should be avoided if 
possible. On the other hand, imatinib is still the most impor-
tant drug for the therapy of CML and GIST, and moreover 
the pk of alternative tyrosine kinase inhibitors is presumably 
also altered by EIAEDs. 
  To improve the knowledge about the influence of the 
various EIAEDs on the imatinib pk, we determined trough 
levels of imatinib and CGP74588 in a collective of 224 
GBM patients. The analysed imatinib trough level confirm 
the results that were found in earlier studies and in addition 
demonstrate, that the imatinib pk from GBM patients with-
out EIAED application is not different from the pk in CML 
patients. 
PATIENTS AND METHODS 
Patients and Sample Collection 
  We analyzed trough levels of imatinib and CGP74588 in 
a total of 224 patients (age 19 to 69 years, median 51 years) 
with histologically confirmed diagnosis of glioblastoma mul-
tiforme/ astrocytome WHO grade IV who received 300 - 
600mg imatinib o.d. (once daily) and 2 - 3 x 500mg Hy-
droxyurea p.o. daily. The differences of the median age and 
gender in the compared trough level groups were not signifi-
cant. All presented trough levels were linearly calculated for 
a 600mg / o.d. dose of imatinib. Group A consists of 111 
patients treated with imatinib and HU without antiepileptic 
co-medication (non-AED), Group B consists of 28 patients 
treated with imatinib and HU in combination with non-
EIAEDs,GroupCconsistsof85 patients treated with imatinib 
and HU in combination with EIAEDs. In group B (non-
EIAED) 4 patients received lamotrigine, 15 valproic acid and 
9 levetiracetam. In group C (EIAED) 15 patients received 
phenytoin, 63 carbamazepine, 6 oxcarbazepine and 1 topi-
ramate. Patients who were concomitantly treated with other 
CYP3A4 inducing drug compounds were excluded. At the 
beginning of treatment all patients had adequate renal (serum 
creatinine  1.5 x ULN), hepatic (SGOT and SGPT  2.5 x 
ULN, total bilirubin  1,5 x ULN) and bone marrow (ANC 
1.5 x 109/L, platelets  100 x 109/L and Hgb >10g/dL) func-
tion. 
  Blood samples were scheduled on week 2, 4, 6, 18, 30 
and 42 of the study prior to the morning dosage administra-
tion, but only in a small portion of patients all scheduled 
samples were drawn in this multicenter study (543 samples 
from 224 patients). Samples were centrifuged at 1000g for 
10min, 1ml of plasma was separated, stored at –20°C and 
sent by express mail to our laboratory for analysis.  
HPLC Measurement  
  The concentration of Imatinib and CGP74588 was de-
termined using a single high performance liquid chromato-
graph method with ultraviolet detection. After protein pre-
cipitation samples were prepared and both substances were 
online enriched on a Zirchrom-PBD (ZirChrom Separations, 
USA, Anoka) guard column. Analysis was performed with a 
Zirchrom-PBD analytical column followed by ultraviolett 
detection at 260nm. Lower limit of quantification was 
10ng/ml for both Imatinib and CGP74588. The intra-day 
precision in plasma samples, as expressed by the coefficient 
of variation, ranges between 1.74% and 8.60% for imatinib 
and 1.45% and 8.87% for CGP74588, depending on the con-
centration. The inter-day precision for a plasma concentra-
tion of 1000 ng/ml analyzed over a 7-month time period was 
8.31% for imatinib and 6.88% for CGP74588. 
  The method was validated and is established for routine 
use as described previously [22-24]. The GINA star software 
(Raytest, Straubenhardt, Germany) was used for data acqui-
sition, evaluation and integration of chromatograms.  
Pharmacokinetics 
  All trough concentrations of imatinib and CGP74588 
were determined after the patients had received imatinib for 
at least two weeks. In consideration of the half- life of 
imatinib (16.5- 26h) and CGP74588 (29,5- 73,5h) within this 
period all patients should have reached pseudo steady state 
conditions [23-25]. The obtained data were compared be-
tween treatment groups, and with historical concentrations 
and simulations from CML patients (Reference). The mean, 
median, maximum (max), minimum (min), standard devia-
tion (SD) and coefficients of variation (CV) were calculated 
for the trough concentrations using the Microsoft excel soft-
ware. 
Statistical Analysis 
  The statistical analysis was performed using Excel and 
SPSS for Windows. Comparisons between groups were per-
fomed using a t-test for independent samples. The resulting 
trough levels are presented as means, standard deviation 
(±SD) and coefficient of variation (CV), if not otherwise 
indicated. Differences were considered as statistically sig-
nificant if a P-value < 0.05 was achieved. 
RESULTS 
  The results of the measured imatinib and CGP74588 
steady-state trough concentrations in 543 plasma samples 
from the enrolled 224 GBM patients are summarized in ta-
bles 1 and 2 for a dose of 600mg imatinib o.d. No significant 
differences in trough level of imatinib were observed be-
tween group A (non-AED) Ctrough = 1404 ng/ml (CV 64%) 
and group B (non-EIAED) Ctrough = 1374 ng/ml (CV 46%). 
Analogous results were found for CGP74588, group A Ctrough
= 356 ng/ml (CV 52%) and group B (non-EIAED) Ctrough = 
351 ng/ml (CV 34%). The parameters which were obtained 
previously from hematological patients, Ctrough = 1400ng/ml 
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Table 1.  Mean Trough Levels and Statistical Parameters for Imatinib Mesylate and CPG74588 in GBM Patients (All Data refer to 
a 600mg Imatinib o.d. Application) 
Group B 
Non EIAED Antiepileptics 
Group C 
EIAED Antiepileptics 
not  
Clearly Classified 
Group A 
no  
Antiepileptics
Valproic Acid Levetiracetam Phenytoin Carbamazepine  Oxcarbazepine Topiramate Lamotrigine
n samples  224 28  24  22 199  33  4 9 
n patients  111 15  9  15 63  6  1 4 
  imatinib trough level in ng/ml 
Mean ng/ml 1404 1399 1369  380  473  534  722  1466 
SD ng/ml  899 664 640  266 358  193 199  405 
CV in %  64 47 47  70 76  36 28  28 
Median in 
ng/ml 
1245 1264 1206  390  363  569  724  1249 
Max in 
ng/ml 
6881 3368 2678  1001 1952  868  960  2019 
Min in ng/ml 38 235  383  22 14  127 481  1050 
  CGP74588 trough level in ng/ml 
Mean ng/ml 356 355 347  268 240  216 291  431 
SD ng/ml  186 117 123  196 137  86  140  107 
CV in %  52 33 36  73 57  40 48  25 
Median in 
ng/ml 
323 311 338  205 209  204 297  420 
Max in 
ng/ml 
1482 616  663  768 724  464  455  577 
Min in ng/ml 27 192  170  45 40  50 114  278 
Table 2. Mean Trough Levels in Three GBM Patient Groups and in CML Patients. All Data refer to a 600mg Imatinib o.d. Appli-
cation 
Group A 
no-AED 
Group B 
non-EIAED  
Group C 
EIAED 
CML 
Patients 
imatinib trough level in ng/ml 
mean in ng/ml  1404 1374  477 1400 
SD in ng/ml  899 631 335 700 
CV in %  64 46 70 50 
CGP74588 trough level in ng/ml 
mean in ng/ml  356 351 240 300 
SD in ng/ml  186 121 137 150 
CV in %  52 34 57 50 
Ratio CGP74588/imatinib in % 
mean in %  25 26 46 21 Influence of Enzyme-Inducing Antiepileptic Drugs  Current Clinical Pharmacology, 2008, Vol. 3, No. 3   201
CGP74588 were quite similar to those seen in groups A and 
B. Even within group B the comparison of separate drug 
compounds levetiracetam (imatinib: Ctrough = 1369 ng/ml,CV 
47%; CGP74588: Ctrough = 347 ng/ml, CV 36%), lamotrigine 
(imatinib: Ctrough = 1466ng/ml, CV 28%; CGP74588: Ctrough
= 431ng/ml, CV 25%) and valproic acid (imatinib: Ctrough = 
1399ng/ml, CV 47%; CGP74588: Ctrough = 355ng/ ml, CV 
33%) showed no significant difference. 
  The patients treated with EIAEDs (group C) showed a 
significant decrease of about 68% in the steady-state level of 
Imatinib Ctrough = 477 ng/ml (CV 70%, P<0.05) compared to 
the other groups. Furthermore the values within group C had 
a greater variability as compared to groups A and B. Patients 
receiving phenytoin showed the lowest concentrations of 
imatinib: Ctrough = 380 ng/ml (CV 70%), followed by Ctrough = 
473ng/ml (CV 76%) for patients on carbamazepine. In the 
oxcarbazepine group we obtained a Ctrough = 534 ng/ml (CV 
36%) and from one patient taking topiramate four measured 
plasma samples gave Ctrough = 722ng/ml (CV 28%). Thus the 
decrease in imatinib trough level in group C ranged from 
about 73% to about 48% compared to groups A and B. In 
contrast the influence of EIAEDs on metabolite were less 
remarkable but although significant. For CGP74588 a mean 
Ctrough = 240 ng/ml (CV 59%, P<0.05) was found corre-
sponding to a decrease of about 32% compared to group A 
and B. Within group C for phenytoin (Ctrough = 268 ng/ml CV 
73%), carbamazepine (Ctrough = 240 ng/ml CV 57%) and ox-
carbazepine (Ctrough = 216 ng/ml CV 40%) quite similar val-
ues were found. Only the patient on topiramate showed a 
slightly higher CGP74588 level Ctrough = 291ng/ml CV 48%.  
 Figs.  (1 and 2) compares the mean imatinib and 
CGP74588 trough level results of group A (non-AED) plus 
B (non-EIAEDs) to group C (EIAEDs), depicted on the cal-
culated plasma curves from CML patients. They show that 
the mean trough level of group A plus B fits nearly perfectly 
to the the CML curves, while for group C significant de-
creases were observed.  
  The mean CGP74588 to imatinib concentration ratios for 
groups A, B and for patients with CML were 25%, 26% and 
21%, respectively. Due to the higher decrease of imatinib 
concentrations compared to CGP74588 the ratio in patients 
on EIAEDs was high, 50%. 
DISCUSSION 
  In the present investigation, EIAED- treated patients dis-
played a significantly reduced trough level of imatinib in 
comparison with patients who were on non-EIAEDs or did 
not take AEDs, respectively. The respective differences were 
less pronounced but although significant for CGP74588. In a 
recent publication, Wen et al. evaluated plasma concentra-
tions of imatinib and CGP74588 in 11 patients that were 
concomitantly treated with EIAEDs and the same number of 
patients not receiving EIAEDs. Results demonstrate a de-
crease of imatinib plasma AUC of about 70% and of 
CGP74588 plasma AUC of about 10%, respectively. The 
overallAUCof imatinib and CGP74588 was reduced 2.7 fold 
whereas the calculated trough concentration Cmin showed a 
decrease of about 79% for imatinib and of about 40% for 
CGP74588 [20]. Table 3 compares these findings to our 
Fig. (1). Differences between the mean trough level of imatinib in patients on EIAEDs and without EIAEDs compared to the mean imatinib 
trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of imatinib and black vertical bars 
indicate the standard deviation. The red curve represents the calculated mean imatinib plasma decay curve under pseudo steady-state condi-
tions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation. 202 Current Clinical Pharmacology, 2008, Vol. 3, No. 3 Pursche et al. 
study. The results of this investigation are in line with our 
findings of 68% (about 2.9 fold) and 32% decline in trough 
levels of imatinib and CGP74588 in patients receciving EI-
AEDs. Additionally, our results are confirmed by the report 
of Reardon et al., where 17 patients with GBM were treated 
with imatinib and HU. The patients (n=8), who were not 
receiving EIAEDs had pharmacokinetic values comparable 
to those from patients with haematological malignancies and 
GIST. In contrast, patients (n=9) receiving EIAEDs showed 
a significant shorter t1/2, a lower AUC and higher Clapp than 
the other group. The influence of EIAEDs on the pharma-
cokinetics of CGP74588 was only moderate [15]. Similar
effectswere seenafter pretreatment with the CYP3A4 induc-
tor rifampicin in healthy volunteers with a 70% decrease of 
the AUC of imatinib. The slight increase in the concentration 
of CGP74588 observed in that report might be explained by 
the fact that patients had received only two single doses of 
imatinib within two weeks and therefore had not reached 
steady-state levels of imatinib and CGP74588 [21].  
  Within the group of EIAEDs, the effects of phenytoin 
and carbamazepine on imatinib trough levels were compara-
ble. As expected, thee effect of oxcarbazepine, a weaker 
CYP3A4 inducer on imatinib exposure was less profound. 
The patient receiving topiramate showed a less prominent 
decrease of imatinib concentrations (48%) compared to the 
rest of the EIAED group (68%) [17]. Since the data on topi-
ramate-imatinib interaction are derived from one patient 
only, this result has to be interpreted with caution. But still, 
the observation would fit very well to the less pronounced 
enzyme-inducing activity reported for topiramat. These re-
sults suggest that a considerable increase of the individual 
imatinib dose may be considered in patients on EIAEDs. 
Reardon et al. reported that in patients with GBM on EI-
AEDs who received HU and 1000 mg imatinib, the imatinib 
Table 3. Dose-Normalized Trough Levels Published by Wen et al. Compared with the Data in the Present Study 
Wen et al. 2006 [20]  Present Study 
Dose-normalized Cmin/through
(ng/ml/mg) at steady state 
non-EIAED EIAED  no-AED non-EIAED  EIAED CML  Patients 
Mean imatinib  2.8 0.58  2.34 2.29  0.80 2.33 
Mean CPG74588  0.70 0.42 0.59  0.59  0.40  0.50 
Mean CPG74588/imatinib ratio  0.25 0.71 0.26  0.26  0.50  0.21 
Fig. (2). Differences between the mean trough level of CGP74588 in patients on EIAEDs and without EIAEDs compared to the mean of 
CGP74588 trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of CGP74588 and black 
vertical bars indicate the standard deviation. The red curve represents the calculated mean CGP74588 plasma decay curve under pseudo 
steady-state conditions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation. Influence of Enzyme-Inducing Antiepileptic Drugs  Current Clinical Pharmacology, 2008, Vol. 3, No. 3   203
exposure remained significantly lower compared to patients 
on non-EIAEDs. Surprisingly, patients with EIAEDs intake 
had an improved progression free survival. On the other 
hand, in spite of the lower AUC of imatinib the observed 
toxicity was significant which lead to a maximum tolerated 
dose of 500mg imatinib twice daily for patients with EIAED 
co-medication [15]. However, patients with CML or GIST 
who receive imatinib and EIAEDs will be at an increased 
risk of not being able to achieve the optimal clinical response 
due to a decreased imatinib exposure. On the other hand, 
patients whose dose is to be escalated should be carefully 
monitored for signs of toxicity or intolerance.  
  In summary, we observed a significant decrease of 
imatinib and CGP74588 exposure in patients taking EI-
AEDs. No significant difference in imatinib trough concen-
trations was observed between GBM patients who did not 
receive AEDs or non-EIAEDs and CML patients. For the 
compounds levetiracetam, lamotrigine and even valproic 
acid, the later being considered as a weak inhibitor of 
CYP3A4 [19], we found no effect on imatinib trough levels. 
Thus, switching to non-EIAEDs if anticonvulsive therapy is 
needed, might be an option for patients receiving imatinib 
treatment. Application of Imatinib and EIAEDs should only 
done if absolutely necessary, and if so in combination with 
repetitively trough level controls. 
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